Sana Biotechnology (SANA) Stock Price, News & Analysis

Company Overview

Sana Biotechnology, Inc. is a clinical-stage biotechnology company dedicated to harnessing the potential of cell engineering and gene therapy to develop curative treatments for a wide array of human diseases. Founded in 2018 and headquartered in Seattle, Washington, with a major research presence in Cambridge, Massachusetts, Sana has built a versatile platform for creating, delivering and regulating engineered cells and genetic material. The company’s mission is to advance the transformation of biological medicines by addressing the root causes of disease through precise, durable interventions.

At the heart of Sana’s approach are two complementary technology platforms: ex vivo cell engineering and in vivo gene delivery. The ex vivo platform involves the isolation, genetic modification and reinfusion of a patient’s own cells to fight hematological and immunological disorders. The in vivo platform enables targeted delivery of gene-editing machinery directly into the body to correct disease-causing genetic defects. By leveraging proprietary delivery vehicles and gene regulation tools, Sana aims to create therapies that can be administered with the simplicity of traditional pharmaceuticals but the durability of cell and gene therapies.

Sana’s pipeline spans multiple therapeutic areas, including blood disorders, metabolic diseases, oncology and ophthalmology. Several early-stage programs have advanced into human clinical trials, reflecting the company’s commitment to rigorous development and robust safety evaluation. Research and development efforts benefit from collaborations with academic institutions and industry partners, expanding Sana’s geographic reach and enabling access to specialized expertise in regulatory affairs, manufacturing and patient care.

Under the leadership of CEO Steve Harr, a former executive at leading life sciences firms, Sana has assembled a seasoned management team with deep experience in molecular biology, translational research and commercial strategy. The board and scientific advisory council include experts in gene editing, stem cell biology and immunotherapy, ensuring that Sana’s strategic direction is guided by cutting-edge science and best practices in biopharmaceutical development. Together, this leadership aims to bring transformative therapies to patients around the world.

Key Stats

• Today's Range: $4.38 to $4.64
• 50-Day Range: $1.68 to $4.63
• 52-Week Range: $1.26 to $7.30
• Volume: 5.02 million shs
• Average Volume: 3.92 million shs
• Market Capitalization: $1.04 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.17
• Consensus Rating: Buy

Sana Biotechnology Stock Analysis - MarketRank™

Sana Biotechnology scored higher than 66% of companies evaluated by MarketBeat, and ranked 369th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Sana Biotechnology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Sana Biotechnology has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Sana Biotechnology are expected to grow in the coming year, from ($1.16) to ($0.84) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Sana Biotechnology is -5.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sana Biotechnology is -5.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Sana Biotechnology has a P/B Ratio of 4.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

29.92% of the float of Sana Biotechnology has been sold short.

Short Interest Ratio / Days to Cover

Sana Biotechnology has a short interest ratio ("days to cover") of 8.4.

Change versus previous month

Short interest in Sana Biotechnology has recently decreased by 13.84%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Sana Biotechnology does not currently pay a dividend.

Dividend Growth

Sana Biotechnology does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

29.92% of the float of Sana Biotechnology has been sold short.

Short Interest Ratio / Days to Cover

Sana Biotechnology has a short interest ratio ("days to cover") of 8.4.

Change versus previous month

Short interest in Sana Biotechnology has recently decreased by 13.84%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: N/A

News Sentiment

Sana Biotechnology has a news sentiment score of 1.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Sana Biotechnology this week, compared to 7 articles on an average week.

Search Interest

18 people have searched for SANA on MarketBeat in the last 30 days. This is an increase of 80% compared to the previous 30 days.

MarketBeat Follows

15 people have added Sana Biotechnology to their MarketBeat watchlist in the last 30 days. This is an increase of 275% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Sana Biotechnology insiders have not sold or bought any company stock.

Percentage Held by Insiders

30.10% of the stock of Sana Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

88.23% of the stock of Sana Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SANA Stock Analysis - Frequently Asked Questions

How have SANA shares performed this year?

Sana Biotechnology's stock was trading at $1.63 at the beginning of the year. Since then, SANA shares have increased by 184.0% and is now trading at $4.63.

How were Sana Biotechnology's earnings last quarter?

Sana Biotechnology, Inc. (NASDAQ:SANA) issued its earnings results on Thursday, May, 8th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.02.

When did Sana Biotechnology IPO?

Sana Biotechnology (SANA) raised $322 million in an initial public offering on Thursday, February 4th 2021. The company issued 15,000,000 shares at a price of $20.00-$23.00 per share. Morgan Stanley, Goldman Sachs, J.P. Morgan and BofA Securities acted as the underwriters for the IPO.

Who are Sana Biotechnology's major shareholders?

Top institutional shareholders of Sana Biotechnology include Palumbo Wealth Management LLC (0.04%), Wealth Enhancement Advisory Services LLC (0.02%), Pallas Capital Advisors LLC (0.02%) and Triumph Capital Management (0.01%). Insiders that own company stock include Robert Nelsen, Fmr Llc, Richard Mulligan, Ventures Fund V Gener Flagship and Joshua H Bilenker.
View institutional ownership trends.

How do I buy shares of Sana Biotechnology?

Shares of SANA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Sana Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Sana Biotechnology investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Walmart (WMT).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/18/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SANA
• CIK: 1770121
• Web: sana.com
• Phone: 206-701-7914
• Fax: N/A
• Employees: 380
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Sana Biotechnology: $9.17
• High Price Target: $15.00
• Low Price Target: $5.00
• Potential Upside/Downside: +98.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.88)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$266.76 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -86.58%
• Return on Assets: -44.49%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.40
• Quick Ratio: 3.40

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.12 per share
• Price / Book: 4.13

Miscellaneous

• Outstanding Shares: 225,480,000
• Free Float: 157,608,000
• Market Cap: $1.04 billion
• Optionable: Optionable
• Beta: 1.86